Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279275 | 0.80 | KDM4C (0.47) | KDM4CKDRROCK1HTT | |
| SCHEMBL2798727 | 0.80 | PLAAT3 (0.39) | KDR | |
| SCHEMBL18755959 | 0.79 | KDM4C (0.41) | KDM4CKDRPRKCICYP19A1CHRNA7 | |
| SCHEMBL4279486 | 0.77 | KDR (0.42) | KDRPIK3CB | |
| SCHEMBL18755989 | 0.77 | KDM4C (0.44) | KDM4CKDRPRKCICHRNA7PIK3CB | |
| SCHEMBL3393029 | 0.75 | HTT (0.51) | KDRCYP2A6GAAHTTMAPT | |
| SCHEMBL27260137 | 0.75 | SCN9A (0.41) | KDM4CGAAHTTHTR2CHTR2B | |
| SCHEMBL18715904 | 0.73 | KDR (0.43) | KDM4CKDRPRKCICHRNA7PIK3CB | |
| SCHEMBL18756352 | 0.73 | KDM4C (0.42) | KDM4CKDRPRKCICHRNA7PIK3CB | |
| SCHEMBL4282699 | 0.73 | CDK5 (0.51) | KDRPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1934200-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007035309-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035309-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149467-A1 | Tyrosine Kinase Inhibitors | ABL1, MET, ERBB2 | KDM4C 1105/4885KDR 165/4885PRKCI 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.